APOBEC3G antibody was raised against a synthetic peptide corresponding to 15 amino acids near the amino-terminus of human APOBEC3G. The immunogen is located within the first 50 amino acids of APOBEC3G.
Conjugation:
Unconjugated
Alternative Names:
A3G,APOBEC-related cytidine deaminase,APOBEC-related protein 9,apolipoprotein B editing enzyme catalytic polypeptide-like 3G,apolipoprotein B mRNA editing enzyme cytidine deaminase,apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G,apolipoprotein B mRNA-editing enzyme catalytic polypeptide 3G,ARCD,ARP9,ARP-9,bK150C2.7,CEM15,CEM-15,deoxycytidine deaminase,dJ494G10.1,DNA dC->dU editing enzyme,DNA dC->dU-editing enzyme APOBEC-3G,MDS019,phorbolin-like protein MDS019.
DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits potent antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double-stranded RNA. Exhibits antiviral activity also against simian immunodeficiency viruses (SIVs), hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV). May inhibit the mobility of LTR and non-LTR retrotransposons.
